<DOC>
	<DOC>NCT03023319</DOC>
	<brief_summary>This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side effects. This study will also test the safety of this combination and see what effects (good or bad) it has on participants and their cancer.</brief_summary>
	<brief_title>Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Thymoma</mesh_term>
	<mesh_term>Thymus Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Pathologically or cytologically proven advanced, metastatic nonsquamous nonsmall cell lung cancer, pleural malignant mesothelioma, bladder or urethral cancer, ovarian cancer, primary peritoneal cancer, thymoma and thymic cancer and uterine cervical cancer. Measurable disease Life expectancy of greater than 3 months. Ability to take folic acid, vitamin B12, and dexamethasone according to protocol. Untreated or symptomatic brain metastases.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>